Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes
about
Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and agingDeterminants of concentrations of N(ε)-carboxymethyl-lysine and soluble receptor for advanced glycation end products and their associations with risk of pancreatic cancerInvolvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategiesAssociation of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS)Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study.Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome.Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancerHigh-mobility group box-1 induces decreased brain-derived neurotrophic factor-mediated neuroprotection in the diabetic retina.sRAGE induces human monocyte survival and differentiationRAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases.RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases.Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory responseAGE and their receptor RAGE in systemic autoimmune diseases: an inflammation propagating factor contributing to accelerated atherosclerosis.Role of Advanced Glycation End Products and Its Receptors in the Pathogenesis of Cigarette Smoke-Induced Cardiovascular Disease.Effect of diet-derived advanced glycation end products on inflammation.Effect of Nɛ-carboxymethyllysine on oxidative stress and the glutathione system in beta cells.Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy.Is Elevated Levels of Serum Soluble Receptor for Advanced Glycation End Products Harmful in Cigarette Smokers?What does Cigarette Smoking do to the Circulating Level of Soluble Receptor for Advanced Glycation End Products?Effects of glycation of the model food allergen ovalbumin on antigen uptake and presentation by human dendritic cells.Effects of ferric citrate supplementation on advanced glycation end products in a rat model of streptozotocin/nicotinamide-induced diabetes.Serum soluble receptor for advanced glycation end products (sRAGE) is independently associated with cigarette smoking in non-diabetic healthy subjects.The Role of Advanced Glycation End Products in Diabetic Vascular Complications.Pregnancy-associated plasma protein A (PAPP-A) and soluble receptor for advanced glycation end products (sRAGE) – intra- and inter-individual variability in chronic hemodialysis patientsAnti-inflammatory effect of biological treatment in patients with inflammatory bowel diseases: Calprotectin and IL-6 changes do not correspond to sRAGE changesRole of the Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Prognostic Factor for Mortality in Hemodialysis and Peritoneal Dialysis Patients
P2860
Q34024272-C974D3B2-E098-4F37-B030-A15B5FC4052CQ34094369-C05EA825-A7F8-4CF5-8F17-55826CD90B69Q34426525-0E7ACBDE-2BCB-4529-B986-6D5DFE27EAB2Q34728267-BDABD472-8E6D-407D-AE8E-34D76ACBA230Q34949171-0852CA47-536D-47D6-BBA0-020918124ED1Q34987953-C73A0BD3-CEC3-4B68-AA10-38F9EE57BA34Q34994616-48826285-CB70-4CA8-9800-6760F9D591C7Q35093747-9A1CEC27-9FBD-4274-A1A5-AA6EE39C33D4Q36900033-06FE16B2-FEDF-42CA-A9EE-08987FB722D0Q36900801-FB7290F8-3743-4540-8DCE-A347E12FD796Q36969021-721E5FDB-B181-46F9-82BA-61B9E8E4958BQ37152947-A2A6AA90-28E9-4FBE-87C1-FE4B3846F98EQ37225236-40BF5B0A-B472-45D6-A2EF-B32DE494B58FQ37259863-C15316AB-06F8-4A48-9CAD-7D3A75BF187AQ37384331-0FE1E715-E7FA-4DC6-940F-63EBC83A6535Q37610425-AFEEFBC3-C49F-4DAC-8ED0-4F531DAB49E4Q38523267-99435507-CE08-4A1C-8B75-121D27601C7FQ38588208-B8E9DB40-487B-4087-8D19-511B464C2DAEQ41681406-842C0B67-829A-408A-B970-95AD31F481E1Q41789363-427BC647-32E3-4F59-AF9D-BA8A375BAFA7Q41975172-216A2041-CAE5-46E9-B76D-E21DEF58AA23Q42781806-4998288E-ED03-4875-B73E-BE3932C0EBB0Q43239563-0F63FEB1-A7A6-4778-87C5-E5D5E95AB9D5Q51318083-425A8883-D9B3-43E3-A7B2-D644FD53D6ACQ51342915-CAAB8AA7-E2F6-47F8-9A4E-99C512F27C7FQ55416114-BA89EB86-98F4-4B92-8A8B-68E018A18A28Q57825168-3633BC00-C60D-489B-BFF2-F3DBA720D902Q57825203-F5970D86-7CA5-40F1-B3C6-1D7D608790C5Q58564998-5870E467-EEB5-47D0-A858-3AC733C923D2
P2860
Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Serum levels of sRAGE, the sol ...... patients with type 2 diabetes
@ast
Serum levels of sRAGE, the sol ...... patients with type 2 diabetes
@en
type
label
Serum levels of sRAGE, the sol ...... patients with type 2 diabetes
@ast
Serum levels of sRAGE, the sol ...... patients with type 2 diabetes
@en
prefLabel
Serum levels of sRAGE, the sol ...... patients with type 2 diabetes
@ast
Serum levels of sRAGE, the sol ...... patients with type 2 diabetes
@en
P2093
P2860
P1433
P1476
Serum levels of sRAGE, the sol ...... patients with type 2 diabetes
@en
P2093
Hisashi Adachi
Kazuo Nakamura
Sho-ichi Yamagishi
Takafumi Yoshida
Takanori Matsui
Tsutomu Imaizumi
Yayoi Kurita-Nakamura
P2860
P2888
P304
P356
10.2119/2006-00090.NAKAMURA
P407
P577
2007-03-01T00:00:00Z
P6179
1068964974